Semnur Pharmaceuticals, Inc. SMNR
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 163.18M | 160.70M | 157.87M | 152.97M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 167.55M | 164.33M | 160.42M | 155.03M | -- |
| Operating Income | -167.55M | -164.33M | -160.42M | -155.03M | -- |
| Income Before Tax | -167.68M | -164.33M | -160.42M | -155.03M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -167.68 | -164.33 | -160.42 | -155.03 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.68M | -164.33M | -160.42M | -155.03M | -- |
| EBIT | -167.55M | -164.33M | -160.42M | -155.03M | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.82 | -0.81 | -0.79 | -0.77 | -- |
| Normalized Basic EPS | -0.51 | -0.51 | -0.50 | -0.48 | -- |
| EPS Diluted | -0.82 | -0.81 | -0.79 | -0.77 | -- |
| Normalized Diluted EPS | -0.51 | -0.51 | -0.50 | -0.48 | -- |
| Average Basic Shares Outstanding | 879.54M | 849.33M | 819.12M | 801.69M | -- |
| Average Diluted Shares Outstanding | 879.54M | 849.33M | 819.12M | 801.69M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |